Excelsior Biopharma (6496) — Financial Flexibility Index
Excelsior Biopharma (6496) has a Financial Flexibility Index of -0.03x as of December 2025. Free cash flow of NT$-20.81 Million (operating CF NT$-22.21 Million minus capex NT$1.40 Million) represents 0% of total liabilities (NT$679.78 Million). Check Excelsior Biopharma strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Excelsior Biopharma Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Excelsior Biopharma across 9 annual periods. See 6496 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Excelsior Biopharma (2017–2025)
Year-by-year free cash flow to debt coverage for Excelsior Biopharma. For the full company profile including market capitalisation, see 6496 market cap overview.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.15x | NT$-101.78 Million | NT$-138.72 Million | NT$679.78 Million | ▼ -155.8% |
| 2024 | 0.27x | NT$157.35 Million | NT$-99.80 Million | NT$586.89 Million | ▲ +227.9% |
| 2023 | -0.21x | NT$-99.09 Million | NT$-134.75 Million | NT$472.87 Million | ▼ -901.5% |
| 2022 | 0.03x | NT$13.27 Million | NT$5.49 Million | NT$507.53 Million | ▼ -72.9% |
| 2021 | 0.10x | NT$58.70 Million | NT$55.82 Million | NT$608.90 Million | ▼ -88.8% |
| 2020 | 0.86x | NT$532.43 Million | NT$520.81 Million | NT$617.15 Million | ▲ +241.0% |
| 2019 | -0.61x | NT$-149.36 Million | NT$-169.74 Million | NT$244.06 Million | ▼ -221.5% |
| 2018 | 0.50x | NT$136.46 Million | NT$126.92 Million | NT$270.88 Million | ▼ -53.5% |
| 2017 | 1.08x | NT$367.57 Million | NT$349.47 Million | NT$339.37 Million | — |